The Pipeline Research team will continue to be led by Karen Miller, SVP Pipeline Research. Joanna Brewer has been promoted to SVP, Allogeneic Research and will continue leading the allogeneic discovery work. Dennis has been promoted to SVP, Late Stage Development and will continue leading the regulatory affairs team. The first of these trials is SPEARHEAD-1 with ADP-A2M4 – currently open for recruitment of patients with synovial sarcoma or myxoid/round cell liposarcoma. Mark becomes Senior Vice President (SVP), Early Stage Development and previously served as SVP, Product Development.Ī Late Stage Development group, led by Dennis Williams, will take products through Phase 2/3 trials and registration. He performed his residency in Internal Medicine at Temple University Hospital, Philadelphia and GI fellowship at Thomas Jefferson University Hospital, Philadelphia.Ĭhanges to the R&D Leadership that will strengthen the end-to-end scientific and clinical development from early to late stage, include:Īn Early Stage Development group, led by Mark Dudley, will evaluate therapies in Phase 1 studies for safety as well as determining their potential for efficacy and further clinical development. Norry practiced adult internal medicine at Abington Memorial Hospital in Abington, Pennsylvania for 13 years. Prior to his work in the biotech and pharmaceutical industries, Dr. Prior to joining Adaptimmune, he served as Safety Development Leader and was Chair of the Hepatic Safety Panel at GSK. He has been acting Chief Medical Officer since August 2019. Norry has served as Head of Clinical Safety and Pharmacovigilance and leader of the ADP-A2AFP program since 2015.
“In addition, we have made changes to our R&D leadership to accelerate how our products move from research to late stage development, including rapid application of translational learnings that are crucial to bringing cell therapies to patients.”ĭr. I look forward to continuing to work with Elliot to deliver cell therapy treatments to patients with cancer,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. This builds on his impact leading the ADP-A2AFP program in liver cancer as well as leading our safety and pharmacovigilance team over the last four years. “Elliot has done a fantastic job as acting CMO over the past few months. Elliot Norry as Senior Vice President and Chief Medical Officer (CMO) effective immediately, and additional changes to its R&D organization. 13, 2020 (GLOBE NEWSWIRE) - Adaptimmune Therapeutics plc ( ADAP), a leader in cell therapy to treat cancer, today announced the appointment of Dr. PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. Thoughts please, I'm getting to the point where I don't even want to marry as I'm fed up of friends and family ruining our ideas and dreams with their opinions.Organizational changes strengthen scientific and clinical development from early to late stage, and accelerate application of translational science learnings to therapeutic candidates and trials What do we do? Do we carry on and go to Mexico with the people who will come or do we change our dreams and go to Spain or Greece? And both our Grandmother's won't come to Mexico. My brother, his wife and nephew can only come in one set week which isn't the time we want to marry and also will not come to Mexico.
My MOH and my partners Best man are together with a child, they now will not come unless we change to Spain or Greece. So we have put this forward to our friends and family who we really want there and now we are facing issues. We have been and priced this up today and we are incredibly happy. Myself and partner got engaged 7 months ago and we quite quickly asked our friends who we wanted in our wedding party (e.g bridesmaids, MOH and best men etc) who all agreed.Īfter searching many English venues we have decided that we want to marry abroad, our dream is Mexico.